Form 4: Third Rock Ventures Sells TNGX Shares

Third Rock Ventures, a 10% owner and director of Tango Therapeutics, Inc., reported the sale of 1.1 million common shares for approximately $7.71 million.

Summary

• Third Rock Ventures IV, L.P., identified as a 10% owner and director of Tango Therapeutics, Inc. (TNGX), sold 1,100,000 shares of the company's common stock.
• The transaction occurred on August 19, 2025.
• The shares were sold at a weighted average price of $7.0116 per share, with individual transaction prices ranging from $7.00 to $7.12.
• The total value of the shares sold is approximately $7,712,760.
• Following this transaction, Third Rock Ventures IV, L.P. directly holds 15,759,075 shares of Tango Therapeutics common stock.
• The sale was executed pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged transaction.

Sentiment

Score: 4

Explanation: The sale of a significant number of shares by a 10% owner and director, even if pre-planned, generally carries a slightly negative sentiment as it reduces insider alignment. However, the Rule 10b5-1 plan mitigates the negative impact by indicating a pre-scheduled, non-opportunistic transaction.

Positives

• The sale was conducted under a Rule 10b5-1(c) plan, which suggests a pre-scheduled transaction rather than an opportunistic sale based on new, non-public information, potentially mitigating negative market perception.

Negatives

• A significant sale of 1,100,000 shares by a 10% owner and director reduces insider ownership, which can be perceived negatively by investors as a decrease in alignment with shareholder interests.

Risks

• Reduced insider ownership by a significant institutional investor and director may signal a potential lack of confidence or a strategic portfolio rebalancing, which could influence investor sentiment.

Future Outlook

The filing does not provide any forward-looking statements or guidance regarding the company's future performance or strategic direction, focusing solely on the reported insider transaction.

Management Comments

• Kevin Gillis, Chief Operating Officer of TRV GP IV, LLC, stated that the reporting person undertakes to provide full information regarding the number of shares sold at each separate price within the reported range upon request.

Industry Context

This insider sale by a venture capital firm, which also holds a director position, is a routine disclosure for publicly traded biotechnology companies. Such transactions are common for venture capital funds as they manage their portfolio liquidity and return capital to limited partners, especially as companies mature or achieve certain milestones. It does not inherently reflect on the operational performance or pipeline progress of Tango Therapeutics, Inc. but rather on the investment strategy of Third Rock Ventures.

Related Party Transactions

• Third Rock Ventures IV, L.P., a 10% owner and director of Tango Therapeutics, Inc., sold 1,100,000 shares of the company's common stock.

Stakeholder Impact

• Shareholders may perceive the reduction in insider ownership by a significant institutional investor as a negative signal, potentially influencing stock price.
• The transaction does not directly impact employees, customers, suppliers, or creditors.

Key Dates

Recommendation

While the significant sale by a 10% owner and director could be seen as a negative signal, the fact that it was executed under a Rule 10b5-1 plan suggests a pre-arranged liquidity event rather than a reaction to new, adverse information. Without additional context on the company's fundamentals or the fund's overall portfolio strategy, this single transaction is not sufficient to warrant a 'sell' recommendation, but it does introduce a cautionary note, leading to a 'hold' stance.

Keywords

Tango Therapeutics, TNGX, Third Rock Ventures, SEC Form 4, Insider Sale, Stock Transaction, Beneficial Ownership, Rule 10b5-1, Biotechnology, Pharmaceuticals